Syndax Pharmaceuticals, Inc.
SNDX
$11.75
$0.595.29%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 44.88% | 44.20% | 136.63% | 310.97% | -- |
| Gross Profit | -10.98% | -25.84% | -114.96% | -300.90% | -- |
| SG&A Expenses | 78.10% | 80.63% | 95.03% | 103.35% | 103.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 47.04% | 58.01% | 73.75% | 68.62% | 63.72% |
| Operating Income | -30.45% | -47.71% | -65.50% | -66.60% | -63.72% |
| Income Before Tax | -37.64% | -52.25% | -68.71% | -64.70% | -56.97% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -37.64% | -52.25% | -68.71% | -64.70% | -56.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -37.64% | -52.25% | -68.71% | -64.70% | -56.97% |
| EBIT | -30.45% | -47.71% | -65.50% | -66.60% | -63.72% |
| EBITDA | -30.45% | -47.72% | -65.51% | -66.61% | -63.74% |
| EPS Basic | -19.97% | -25.83% | -40.47% | -38.68% | -33.10% |
| Normalized Basic EPS | -19.97% | -25.83% | -40.48% | -38.69% | -33.10% |
| EPS Diluted | -19.78% | -25.64% | -40.56% | -38.78% | -33.20% |
| Normalized Diluted EPS | -19.97% | -25.83% | -40.48% | -38.69% | -33.10% |
| Average Basic Shares Outstanding | 15.29% | 21.41% | 20.70% | 18.99% | 17.27% |
| Average Diluted Shares Outstanding | 15.29% | 21.41% | 20.70% | 18.99% | 17.27% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |